{
    "info": {
        "nct_id": "NCT02906397",
        "official_title": "A Pilot Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)",
        "inclusion_criteria": "* Patients must have histologically confirmed hepatocellular carcinoma (HCC) that is inoperable (where surgery is not indicated due to disease extension, co-morbidities or other technical reasons)\n* ≥18 years of age and ability to understand and the willingness to sign a written informed consent document. A legally authorized representative signature in the event that the subject is not able to sign themselves is permitted.\n* Patients must have either not been eligible for sorafenib therapy, have failed sorafenib therapy, have discontinued sorafenib therapy due to intolerable toxicity or have refused sorafenib\n* ECOG performance status ≤2\n* Childs Pugh score of ≤7\n* Life expectancy of at least 12 weeks\n* Must be able to swallow tablets\n* Must be willing to comply with protocol procedures (including completion of diaries and outcome measures)\n* Local or loco-regional therapy (ie surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) must have been completed ≥4 weeks prior to enrollment\n* Must be willing to undergo a pretreatment biopsy\n* A history of prior radiotherapy is permitted, as long as the prior radiated site is not overlapping with the site of planned SBRT\n* Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1\n* An index lesion measuring between 1cm-10cm that is amenable to hypofractionated radiation therapy at the discretion of the treating radiation oncologist\n* Women of childbearing potential must have a negative serum pregnancy test performed at screening\n* Subjects must use an approved contraceptive method (for example, intrauterine device, birth control pills or barrier device) which has an expected failure rate of <1%, if appropriate for at least 3 months after the last dose of galunisertib.\n\nPatients who are HIV-positive are eligible if:\n\n* CD4+ cell count is greater or equal to 250cells/mm3.\n* If patient is on retroviral therapy, there must be minimal interactions or -overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment.\n* No history of non-malignancy AIDS defining conditions other than low CD4+ count.\n* Probable long-term survival with HIV if cancer were not present.\n* Must have adequate organ and hematopoietic function as defined below:\n\nLaboratory Test Required Value Absolute neutrophil count ≥1.5 x 10^9/L Platelet count ≥100 x 10^9/L Hemoglobin ≥9.0 x 10^9/L Alanine transaminase ≤2.5 x ULN Aspartate aminotransferase ≤2.5 x ULN Serum creatinine or CrCl ≤2.0 x ULN Total Bilirubin ≤1.5 x ULN\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Any history of a serious medical or psychiatric condition that would prevent the patient from signing the informed consent form\n* Pregnant or breastfeeding women.\n* Use of any other chemotherapy, radiotherapy or experimental drug within 4 weeks prior to first study treatment date\n* A history of radiotherapy that, in the opinion of the investigator, would render SBRT unsafe to administer\n* Those who have not recovered from adverse events ≤ grade 1 secondary to therapy administered >4 weeks prior to first study treatment date, with the exception of stable grade 2 neuropathy\n* Subjects may not receive concomitant anticancer agents. Antiviral agents aimed at treating infectious hepatitis are permitted\n* History of or suspected hypersensitivity to radiation or to galunisertib\n* Uncontrolled ascites\n* Subjects with a history of or evidence of cardiac disease during screening, defined as any one of the following: myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, uncontrolled hypertension.\n* Subjects with a documented major ECG abnormalities (not responding to medical treatments) or not clinically stable for at least 6 months.\n* Subjects with major abnormalities documented by ECHO with Doppler (for example, moderate or severe heart valve function defect) that is not stable for at least 6 months.. Note: Left ventricular [LV] ejection fraction <50% is allowed only if clinically stable for at least 6 months (evaluation based on the institutional lower limit of normal).\n* Subjects with a predisposition toward developing aneurysms of the ascending aorta or aortic stress including a family history of aneurysms, Marfan Syndrome, Ehlers Danlos Type IV, bicuspid aortic valve or evidence of damage to the large vessels of the heart documented by previously obtained or screening CT scan/MRI\n* Subjects with uncontrolled brain metastases. Subjects with brain metastases must have stable neurological status following local therapy (surgery or radiation) for at least 4 weeks prior to first study treatment and must be off steroids\n* Any concurrent condition requiring the continued or anticipated use of systemic steroids beyond physiologic replacement dosing (excluding non-systemic inhaled, topical skin and/or eye drop-containing corticosteroids) or immunosuppressive therapy (excludes low-dose methotrexate). All other systemic corticosteroids above physiologic replacement dosing must be discontinued at least 4 weeks prior to first study treatment\n* Active drug or alcohol use or dependence as documented in the chart that, in the opinion of the investigator, would interfere with adherence to study requirements\n* A second primary malignancy that, in the judgment of the investigator, may affect the interpretation of results\n* Prior malignancies. Patients with carcinoma in-situ of any origin and patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma) as judged by the Lilly clinical research physician (CRP), are eligible.\n* Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint\n* Any other conditions judged by the investigator that would limit the evaluation of the subject",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "identified_line": {
                "line": "* Probable long-term survival with HIV if cancer were not present.",
                "criterions": [
                    {
                        "exact_snippets": "Probable long-term survival with HIV if cancer were not present.",
                        "criterion": "long-term survival with HIV",
                        "requirement": {
                            "requirement_type": "probability",
                            "expected_value": "probable"
                        }
                    },
                    {
                        "exact_snippets": "Probable long-term survival with HIV if cancer were not present.",
                        "criterion": "long-term survival with HIV",
                        "requirement": {
                            "requirement_type": "conditional_on",
                            "expected_value": "if cancer were not present"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "Probable long-term survival with HIV if cancer were not present.",
                    "criterion": "long-term survival with HIV",
                    "requirement": {
                        "requirement_type": "conditional_on",
                        "expected_value": "if cancer were not present"
                    }
                },
                "then_criteria": {
                    "exact_snippets": "Probable long-term survival with HIV if cancer were not present.",
                    "criterion": "long-term survival with HIV",
                    "requirement": {
                        "requirement_type": "probability",
                        "expected_value": "probable"
                    }
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Must have adequate organ and hematopoietic function as defined below:",
                "criterions": [
                    {
                        "exact_snippets": "adequate organ and hematopoietic function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "adequate organ and hematopoietic function",
                        "criterion": "hematopoietic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "adequate organ and hematopoietic function",
                        "criterion": "organ function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "adequate organ and hematopoietic function",
                        "criterion": "hematopoietic function",
                        "requirement": {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients must have either not been eligible for sorafenib therapy, have failed sorafenib therapy, have discontinued sorafenib therapy due to intolerable toxicity or have refused sorafenib",
                "criterions": [
                    {
                        "exact_snippets": "not been eligible for sorafenib therapy",
                        "criterion": "sorafenib therapy eligibility",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "have failed sorafenib therapy",
                        "criterion": "sorafenib therapy outcome",
                        "requirement": {
                            "requirement_type": "treatment failure",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "have discontinued sorafenib therapy due to intolerable toxicity",
                        "criterion": "sorafenib therapy discontinuation due to toxicity",
                        "requirement": {
                            "requirement_type": "discontinuation",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "have discontinued sorafenib therapy due to intolerable toxicity",
                        "criterion": "sorafenib therapy discontinuation due to toxicity",
                        "requirement": {
                            "requirement_type": "reason for discontinuation",
                            "expected_value": "intolerable toxicity"
                        }
                    },
                    {
                        "exact_snippets": "have refused sorafenib",
                        "criterion": "sorafenib therapy refusal",
                        "requirement": {
                            "requirement_type": "refusal",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "not been eligible for sorafenib therapy",
                        "criterion": "sorafenib therapy eligibility",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "have failed sorafenib therapy",
                        "criterion": "sorafenib therapy outcome",
                        "requirement": {
                            "requirement_type": "treatment failure",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "have discontinued sorafenib therapy due to intolerable toxicity",
                                "criterion": "sorafenib therapy discontinuation due to toxicity",
                                "requirement": {
                                    "requirement_type": "discontinuation",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "have discontinued sorafenib therapy due to intolerable toxicity",
                                "criterion": "sorafenib therapy discontinuation due to toxicity",
                                "requirement": {
                                    "requirement_type": "reason for discontinuation",
                                    "expected_value": "intolerable toxicity"
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "have refused sorafenib",
                        "criterion": "sorafenib therapy refusal",
                        "requirement": {
                            "requirement_type": "refusal",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Patients who are HIV-positive are eligible if:",
                "criterions": [
                    {
                        "exact_snippets": "Patients who are HIV-positive",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Patients who are HIV-positive",
                        "criterion": "HIV status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Healthy volunteers allowed",
                "criterions": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Healthy volunteers allowed",
                        "criterion": "healthy volunteer status",
                        "requirement": {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Must be willing to comply with protocol procedures (including completion of diaries and outcome measures)",
                "criterions": [
                    {
                        "exact_snippets": "Must be willing to comply with protocol procedures",
                        "criterion": "willingness to comply with protocol procedures",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including completion of diaries",
                        "criterion": "completion of diaries",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including ... outcome measures",
                        "criterion": "completion of outcome measures",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must be willing to comply with protocol procedures",
                        "criterion": "willingness to comply with protocol procedures",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including completion of diaries",
                        "criterion": "completion of diaries",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "including ... outcome measures",
                        "criterion": "completion of outcome measures",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "Must have minimum age of 18 Years",
                "criterions": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "minimum age of 18 Years",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Life expectancy of at least 12 weeks",
                "criterions": [
                    {
                        "exact_snippets": "Life expectancy of at least 12 weeks",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Life expectancy of at least 12 weeks",
                        "criterion": "life expectancy",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
                "criterions": [
                    {
                        "exact_snippets": "Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "definition standard",
                            "expected_value": "RECIST version 1.1"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "measurability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Measurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1",
                        "criterion": "disease measurability",
                        "requirement": {
                            "requirement_type": "definition standard",
                            "expected_value": "RECIST version 1.1"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Childs Pugh score of ≤7",
                "criterions": [
                    {
                        "exact_snippets": "Childs Pugh score of ≤7",
                        "criterion": "Child-Pugh score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Childs Pugh score of ≤7",
                        "criterion": "Child-Pugh score",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* CD4+ cell count is greater or equal to 250cells/mm3.",
                "criterions": [
                    {
                        "exact_snippets": "CD4+ cell count is greater or equal to 250cells/mm3",
                        "criterion": "CD4+ cell count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 250,
                                "unit": "cells/mm3"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "CD4+ cell count is greater or equal to 250cells/mm3",
                        "criterion": "CD4+ cell count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 250,
                                "unit": "cells/mm3"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* ECOG performance status ≤2",
                "criterions": [
                    {
                        "exact_snippets": "ECOG performance status ≤2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "ECOG performance status ≤2",
                        "criterion": "ECOG performance status",
                        "requirement": {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Women of childbearing potential must have a negative serum pregnancy test performed at screening",
                "criterions": [
                    {
                        "exact_snippets": "Women of childbearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        }
                    },
                    {
                        "exact_snippets": "Women of childbearing potential",
                        "criterion": "sex and reproductive status",
                        "requirement": {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "must have a negative serum pregnancy test performed at screening",
                        "criterion": "serum pregnancy test at screening",
                        "requirement": {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        }
                    },
                    {
                        "exact_snippets": "must have a negative serum pregnancy test performed at screening",
                        "criterion": "serum pregnancy test at screening",
                        "requirement": {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "and_criteria": [
                        {
                            "exact_snippets": "Women of childbearing potential",
                            "criterion": "sex and reproductive status",
                            "requirement": {
                                "requirement_type": "sex",
                                "expected_value": "female"
                            }
                        },
                        {
                            "exact_snippets": "Women of childbearing potential",
                            "criterion": "sex and reproductive status",
                            "requirement": {
                                "requirement_type": "childbearing potential",
                                "expected_value": true
                            }
                        }
                    ]
                },
                "then_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "must have a negative serum pregnancy test performed at screening",
                            "criterion": "serum pregnancy test at screening",
                            "requirement": {
                                "requirement_type": "result",
                                "expected_value": "negative"
                            }
                        },
                        {
                            "exact_snippets": "must have a negative serum pregnancy test performed at screening",
                            "criterion": "serum pregnancy test at screening",
                            "requirement": {
                                "requirement_type": "timing",
                                "expected_value": "at screening"
                            }
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Must be willing to undergo a pretreatment biopsy",
                "criterions": [
                    {
                        "exact_snippets": "Must be willing to undergo a pretreatment biopsy",
                        "criterion": "willingness to undergo pretreatment biopsy",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must be willing to undergo a pretreatment biopsy",
                        "criterion": "willingness to undergo pretreatment biopsy",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A history of prior radiotherapy is permitted, as long as the prior radiated site is not overlapping with the site of planned SBRT",
                "criterions": [
                    {
                        "exact_snippets": "A history of prior radiotherapy is permitted",
                        "criterion": "prior radiotherapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "the prior radiated site is not overlapping with the site of planned SBRT",
                        "criterion": "overlap of prior radiated site and planned SBRT site",
                        "requirement": {
                            "requirement_type": "overlap",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "A history of prior radiotherapy is permitted",
                        "criterion": "prior radiotherapy",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "the prior radiated site is not overlapping with the site of planned SBRT",
                        "criterion": "overlap of prior radiated site and planned SBRT site",
                        "requirement": {
                            "requirement_type": "overlap",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Patients must have histologically confirmed hepatocellular carcinoma (HCC) that is inoperable (where surgery is not indicated due to disease extension, co-morbidities or other technical reasons)",
                "criterions": [
                    {
                        "exact_snippets": "histologically confirmed hepatocellular carcinoma (HCC)",
                        "criterion": "hepatocellular carcinoma",
                        "requirement": {
                            "requirement_type": "diagnosis confirmation",
                            "expected_value": "histologically confirmed"
                        }
                    },
                    {
                        "exact_snippets": "hepatocellular carcinoma (HCC) that is inoperable (where surgery is not indicated due to disease extension, co-morbidities or other technical reasons)",
                        "criterion": "hepatocellular carcinoma operability",
                        "requirement": {
                            "requirement_type": "operability",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "histologically confirmed hepatocellular carcinoma (HCC)",
                        "criterion": "hepatocellular carcinoma",
                        "requirement": {
                            "requirement_type": "diagnosis confirmation",
                            "expected_value": "histologically confirmed"
                        }
                    },
                    {
                        "exact_snippets": "hepatocellular carcinoma (HCC) that is inoperable (where surgery is not indicated due to disease extension, co-morbidities or other technical reasons)",
                        "criterion": "hepatocellular carcinoma operability",
                        "requirement": {
                            "requirement_type": "operability",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* ≥18 years of age and ability to understand and the willingness to sign a written informed consent document. A legally authorized representative signature in the event that the subject is not able to sign themselves is permitted.",
                "criterions": [
                    {
                        "exact_snippets": "≥18 years of age",
                        "criterion": "age",
                        "requirement": {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    },
                    {
                        "exact_snippets": "ability to understand",
                        "criterion": "cognitive ability",
                        "requirement": {
                            "requirement_type": "ability to understand",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "willingness to sign a written informed consent document",
                        "criterion": "willingness to provide informed consent",
                        "requirement": {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "A legally authorized representative signature in the event that the subject is not able to sign themselves is permitted",
                        "criterion": "legally authorized representative consent",
                        "requirement": {
                            "requirement_type": "representative consent permitted",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "≥18 years of age",
                                "criterion": "age",
                                "requirement": {
                                    "requirement_type": "minimum age",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    }
                                }
                            },
                            {
                                "or_criteria": [
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "ability to understand",
                                                "criterion": "cognitive ability",
                                                "requirement": {
                                                    "requirement_type": "ability to understand",
                                                    "expected_value": true
                                                }
                                            },
                                            {
                                                "exact_snippets": "willingness to sign a written informed consent document",
                                                "criterion": "willingness to provide informed consent",
                                                "requirement": {
                                                    "requirement_type": "willingness",
                                                    "expected_value": true
                                                }
                                            }
                                        ]
                                    },
                                    {
                                        "exact_snippets": "A legally authorized representative signature in the event that the subject is not able to sign themselves is permitted",
                                        "criterion": "legally authorized representative consent",
                                        "requirement": {
                                            "requirement_type": "representative consent permitted",
                                            "expected_value": true
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* An index lesion measuring between 1cm-10cm that is amenable to hypofractionated radiation therapy at the discretion of the treating radiation oncologist",
                "criterions": [
                    {
                        "exact_snippets": "An index lesion measuring between 1cm-10cm",
                        "criterion": "index lesion size",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "cm"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "cm"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "index lesion ... amenable to hypofractionated radiation therapy",
                        "criterion": "index lesion amenability to hypofractionated radiation therapy",
                        "requirement": {
                            "requirement_type": "amenability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "at the discretion of the treating radiation oncologist",
                        "criterion": "treating radiation oncologist discretion",
                        "requirement": {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "An index lesion measuring between 1cm-10cm",
                        "criterion": "index lesion size",
                        "requirement": {
                            "requirement_type": "size",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "cm"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 10,
                                        "unit": "cm"
                                    }
                                ]
                            }
                        }
                    },
                    {
                        "exact_snippets": "index lesion ... amenable to hypofractionated radiation therapy",
                        "criterion": "index lesion amenability to hypofractionated radiation therapy",
                        "requirement": {
                            "requirement_type": "amenability",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "at the discretion of the treating radiation oncologist",
                        "criterion": "treating radiation oncologist discretion",
                        "requirement": {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* If patient is on retroviral therapy, there must be minimal interactions or -overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment.",
                "criterions": [
                    {
                        "exact_snippets": "If patient is on retroviral therapy",
                        "criterion": "retroviral therapy",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "minimal interactions ... of the antiretroviral therapy with the experimental cancer treatment",
                        "criterion": "drug-drug interactions between antiretroviral therapy and experimental cancer treatment",
                        "requirement": {
                            "requirement_type": "interaction level",
                            "expected_value": "minimal"
                        }
                    },
                    {
                        "exact_snippets": "minimal ... -overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment",
                        "criterion": "overlapping toxicity between antiretroviral therapy and experimental cancer treatment",
                        "requirement": {
                            "requirement_type": "toxicity overlap",
                            "expected_value": "minimal"
                        }
                    }
                ]
            },
            "logical_structure": {
                "condition": {
                    "exact_snippets": "If patient is on retroviral therapy",
                    "criterion": "retroviral therapy",
                    "requirement": {
                        "requirement_type": "current use",
                        "expected_value": true
                    }
                },
                "then_criteria": {
                    "and_criteria": [
                        {
                            "exact_snippets": "minimal interactions ... of the antiretroviral therapy with the experimental cancer treatment",
                            "criterion": "drug-drug interactions between antiretroviral therapy and experimental cancer treatment",
                            "requirement": {
                                "requirement_type": "interaction level",
                                "expected_value": "minimal"
                            }
                        },
                        {
                            "exact_snippets": "minimal ... -overlapping toxicity of the antiretroviral therapy with the experimental cancer treatment",
                            "criterion": "overlapping toxicity between antiretroviral therapy and experimental cancer treatment",
                            "requirement": {
                                "requirement_type": "toxicity overlap",
                                "expected_value": "minimal"
                            }
                        }
                    ]
                },
                "else_criteria": null
            }
        },
        {
            "identified_line": {
                "line": "* Must be able to swallow tablets",
                "criterions": [
                    {
                        "exact_snippets": "Must be able to swallow tablets",
                        "criterion": "ability to swallow tablets",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Must be able to swallow tablets",
                        "criterion": "ability to swallow tablets",
                        "requirement": {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects must use an approved contraceptive method (for example, intrauterine device, birth control pills or barrier device) which has an expected failure rate of <1%, if appropriate for at least 3 months after the last dose of galunisertib.",
                "criterions": [
                    {
                        "exact_snippets": "Subjects must use an approved contraceptive method (for example, intrauterine device, birth control pills or barrier device)",
                        "criterion": "contraceptive method",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Subjects must use an approved contraceptive method (for example, intrauterine device, birth control pills or barrier device)",
                        "criterion": "contraceptive method",
                        "requirement": {
                            "requirement_type": "approval status",
                            "expected_value": "approved"
                        }
                    },
                    {
                        "exact_snippets": "contraceptive method ... which has an expected failure rate of <1%",
                        "criterion": "contraceptive method failure rate",
                        "requirement": {
                            "requirement_type": "failure rate",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "for at least 3 months after the last dose of galunisertib",
                        "criterion": "contraceptive method duration after last dose of galunisertib",
                        "requirement": {
                            "requirement_type": "duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Subjects must use an approved contraceptive method (for example, intrauterine device, birth control pills or barrier device)",
                        "criterion": "contraceptive method",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Subjects must use an approved contraceptive method (for example, intrauterine device, birth control pills or barrier device)",
                        "criterion": "contraceptive method",
                        "requirement": {
                            "requirement_type": "approval status",
                            "expected_value": "approved"
                        }
                    },
                    {
                        "exact_snippets": "contraceptive method ... which has an expected failure rate of <1%",
                        "criterion": "contraceptive method failure rate",
                        "requirement": {
                            "requirement_type": "failure rate",
                            "expected_value": {
                                "operator": "<",
                                "value": 1,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "for at least 3 months after the last dose of galunisertib",
                        "criterion": "contraceptive method duration after last dose of galunisertib",
                        "requirement": {
                            "requirement_type": "duration after last dose",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        }
    ],
    "exclusion_lines": [
        {
            "identified_line": {
                "line": "* Subjects may not receive concomitant anticancer agents. Antiviral agents aimed at treating infectious hepatitis are permitted",
                "criterions": [
                    {
                        "exact_snippets": "Subjects may not receive concomitant anticancer agents.",
                        "criterion": "concomitant anticancer agents",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Antiviral agents aimed at treating infectious hepatitis are permitted",
                        "criterion": "antiviral agents for infectious hepatitis",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Subjects may not receive concomitant anticancer agents.",
                        "criterion": "concomitant anticancer agents",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "Antiviral agents aimed at treating infectious hepatitis are permitted",
                        "criterion": "antiviral agents for infectious hepatitis",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A history of radiotherapy that, in the opinion of the investigator, would render SBRT unsafe to administer",
                "criterions": [
                    {
                        "exact_snippets": "A history of radiotherapy that, in the opinion of the investigator, would render SBRT unsafe to administer",
                        "criterion": "history of radiotherapy",
                        "requirement": {
                            "requirement_type": "safety for SBRT",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "A history of radiotherapy that, in the opinion of the investigator, would render SBRT unsafe to administer",
                        "criterion": "history of radiotherapy",
                        "requirement": {
                            "requirement_type": "safety for SBRT",
                            "expected_value": false
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any illness or condition that in the opinion of the investigator may affect the safety of the subject or the evaluation of any study endpoint",
                "criterions": [
                    {
                        "exact_snippets": "Any illness or condition that in the opinion of the investigator may affect the safety of the subject",
                        "criterion": "illness or condition",
                        "requirement": {
                            "requirement_type": "impact on safety",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any illness or condition that in the opinion of the investigator may affect the safety of the subject",
                        "criterion": "illness or condition",
                        "requirement": {
                            "requirement_type": "investigator opinion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any illness or condition that in the opinion of the investigator may affect ... the evaluation of any study endpoint",
                        "criterion": "illness or condition",
                        "requirement": {
                            "requirement_type": "impact on evaluation of study endpoint",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any illness or condition that in the opinion of the investigator may affect ... the evaluation of any study endpoint",
                        "criterion": "illness or condition",
                        "requirement": {
                            "requirement_type": "investigator opinion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any illness or condition that in the opinion of the investigator may affect the safety of the subject",
                                "criterion": "illness or condition",
                                "requirement": {
                                    "requirement_type": "impact on safety",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Any illness or condition that in the opinion of the investigator may affect the safety of the subject",
                                "criterion": "illness or condition",
                                "requirement": {
                                    "requirement_type": "investigator opinion",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any illness or condition that in the opinion of the investigator may affect ... the evaluation of any study endpoint",
                                "criterion": "illness or condition",
                                "requirement": {
                                    "requirement_type": "impact on evaluation of study endpoint",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Any illness or condition that in the opinion of the investigator may affect ... the evaluation of any study endpoint",
                                "criterion": "illness or condition",
                                "requirement": {
                                    "requirement_type": "investigator opinion",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects with a predisposition toward developing aneurysms of the ascending aorta or aortic stress including a family history of aneurysms, Marfan Syndrome, Ehlers Danlos Type IV, bicuspid aortic valve or evidence of damage to the large vessels of the heart documented by previously obtained or screening CT scan/MRI",
                "criterions": [
                    {
                        "exact_snippets": "predisposition toward developing aneurysms of the ascending aorta",
                        "criterion": "predisposition to ascending aorta aneurysm",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "predisposition toward developing ... aortic stress",
                        "criterion": "predisposition to aortic stress",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of aneurysms",
                        "criterion": "family history of aneurysms",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Marfan Syndrome",
                        "criterion": "Marfan Syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Ehlers Danlos Type IV",
                        "criterion": "Ehlers Danlos Type IV",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bicuspid aortic valve",
                        "criterion": "bicuspid aortic valve",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "evidence of damage to the large vessels of the heart documented by previously obtained or screening CT scan/MRI",
                        "criterion": "damage to large vessels of the heart",
                        "requirement": {
                            "requirement_type": "evidence by CT scan/MRI",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "predisposition toward developing aneurysms of the ascending aorta",
                        "criterion": "predisposition to ascending aorta aneurysm",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "predisposition toward developing ... aortic stress",
                        "criterion": "predisposition to aortic stress",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "family history of aneurysms",
                        "criterion": "family history of aneurysms",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Marfan Syndrome",
                        "criterion": "Marfan Syndrome",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Ehlers Danlos Type IV",
                        "criterion": "Ehlers Danlos Type IV",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "bicuspid aortic valve",
                        "criterion": "bicuspid aortic valve",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "evidence of damage to the large vessels of the heart documented by previously obtained or screening CT scan/MRI",
                        "criterion": "damage to large vessels of the heart",
                        "requirement": {
                            "requirement_type": "evidence by CT scan/MRI",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects with a documented major ECG abnormalities (not responding to medical treatments) or not clinically stable for at least 6 months.",
                "criterions": [
                    {
                        "exact_snippets": "documented major ECG abnormalities (not responding to medical treatments)",
                        "criterion": "major ECG abnormalities",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "documented major ECG abnormalities (not responding to medical treatments)",
                        "criterion": "major ECG abnormalities",
                        "requirement": {
                            "requirement_type": "response to medical treatments",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "not clinically stable for at least 6 months",
                        "criterion": "clinical stability",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "documented major ECG abnormalities (not responding to medical treatments)",
                                "criterion": "major ECG abnormalities",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "documented major ECG abnormalities (not responding to medical treatments)",
                                "criterion": "major ECG abnormalities",
                                "requirement": {
                                    "requirement_type": "response to medical treatments",
                                    "expected_value": false
                                }
                            }
                        ]
                    },
                    {
                        "exact_snippets": "not clinically stable for at least 6 months",
                        "criterion": "clinical stability",
                        "requirement": {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Those who have not recovered from adverse events ≤ grade 1 secondary to therapy administered >4 weeks prior to first study treatment date, with the exception of stable grade 2 neuropathy",
                "criterions": [
                    {
                        "exact_snippets": "not recovered from adverse events ≤ grade 1 secondary to therapy administered >4 weeks prior to first study treatment date",
                        "criterion": "recovery from adverse events secondary to prior therapy",
                        "requirement": {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "not recovered from adverse events ≤ grade 1 secondary to therapy administered >4 weeks prior to first study treatment date",
                        "criterion": "recovery from adverse events secondary to prior therapy",
                        "requirement": {
                            "requirement_type": "adverse_event_grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "not recovered from adverse events ≤ grade 1 secondary to therapy administered >4 weeks prior to first study treatment date",
                        "criterion": "recovery from adverse events secondary to prior therapy",
                        "requirement": {
                            "requirement_type": "time_since_prior_therapy",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "with the exception of stable grade 2 neuropathy",
                        "criterion": "neuropathy",
                        "requirement": {
                            "requirement_type": "grade",
                            "expected_value": {
                                "operator": "=",
                                "value": 2,
                                "unit": "grade"
                            }
                        }
                    },
                    {
                        "exact_snippets": "with the exception of stable grade 2 neuropathy",
                        "criterion": "neuropathy",
                        "requirement": {
                            "requirement_type": "stability",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "and_criteria": [
                                            {
                                                "exact_snippets": "not recovered from adverse events ≤ grade 1 secondary to therapy administered >4 weeks prior to first study treatment date",
                                                "criterion": "recovery from adverse events secondary to prior therapy",
                                                "requirement": {
                                                    "requirement_type": "recovery_status",
                                                    "expected_value": true
                                                }
                                            },
                                            {
                                                "exact_snippets": "not recovered from adverse events ≤ grade 1 secondary to therapy administered >4 weeks prior to first study treatment date",
                                                "criterion": "recovery from adverse events secondary to prior therapy",
                                                "requirement": {
                                                    "requirement_type": "adverse_event_grade",
                                                    "expected_value": {
                                                        "operator": "<=",
                                                        "value": 1,
                                                        "unit": "grade"
                                                    }
                                                }
                                            },
                                            {
                                                "exact_snippets": "not recovered from adverse events ≤ grade 1 secondary to therapy administered >4 weeks prior to first study treatment date",
                                                "criterion": "recovery from adverse events secondary to prior therapy",
                                                "requirement": {
                                                    "requirement_type": "time_since_prior_therapy",
                                                    "expected_value": {
                                                        "operator": ">",
                                                        "value": 4,
                                                        "unit": "weeks"
                                                    }
                                                }
                                            }
                                        ]
                                    }
                                ]
                            },
                            {
                                "not_criteria": {
                                    "and_criteria": [
                                        {
                                            "exact_snippets": "with the exception of stable grade 2 neuropathy",
                                            "criterion": "neuropathy",
                                            "requirement": {
                                                "requirement_type": "grade",
                                                "expected_value": {
                                                    "operator": "=",
                                                    "value": 2,
                                                    "unit": "grade"
                                                }
                                            }
                                        },
                                        {
                                            "exact_snippets": "with the exception of stable grade 2 neuropathy",
                                            "criterion": "neuropathy",
                                            "requirement": {
                                                "requirement_type": "stability",
                                                "expected_value": true
                                            }
                                        }
                                    ]
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "with the exception of stable grade 2 neuropathy",
                                "criterion": "neuropathy",
                                "requirement": {
                                    "requirement_type": "grade",
                                    "expected_value": {
                                        "operator": "=",
                                        "value": 2,
                                        "unit": "grade"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "with the exception of stable grade 2 neuropathy",
                                "criterion": "neuropathy",
                                "requirement": {
                                    "requirement_type": "stability",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects with uncontrolled brain metastases. Subjects with brain metastases must have stable neurological status following local therapy (surgery or radiation) for at least 4 weeks prior to first study treatment and must be off steroids",
                "criterions": [
                    {
                        "exact_snippets": "Subjects with uncontrolled brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    },
                    {
                        "exact_snippets": "brain metastases must have stable neurological status following local therapy (surgery or radiation) for at least 4 weeks prior to first study treatment",
                        "criterion": "neurological status after local therapy for brain metastases",
                        "requirement": {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "must be off steroids",
                        "criterion": "steroid use",
                        "requirement": {
                            "requirement_type": "current use",
                            "expected_value": false
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Subjects with uncontrolled brain metastases",
                        "criterion": "brain metastases",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "controlled"
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "brain metastases must have stable neurological status following local therapy (surgery or radiation) for at least 4 weeks prior to first study treatment",
                                "criterion": "neurological status after local therapy for brain metastases",
                                "requirement": {
                                    "requirement_type": "stability duration",
                                    "expected_value": {
                                        "operator": ">=",
                                        "value": 4,
                                        "unit": "weeks"
                                    }
                                }
                            },
                            {
                                "exact_snippets": "must be off steroids",
                                "criterion": "steroid use",
                                "requirement": {
                                    "requirement_type": "current use",
                                    "expected_value": false
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any other conditions judged by the investigator that would limit the evaluation of the subject",
                "criterions": [
                    {
                        "exact_snippets": "Any other conditions judged by the investigator that would limit the evaluation of the subject",
                        "criterion": "other conditions limiting evaluation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any other conditions judged by the investigator that would limit the evaluation of the subject",
                        "criterion": "other conditions limiting evaluation",
                        "requirement": {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Any other conditions judged by the investigator that would limit the evaluation of the subject",
                        "criterion": "other conditions limiting evaluation",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any other conditions judged by the investigator that would limit the evaluation of the subject",
                        "criterion": "other conditions limiting evaluation",
                        "requirement": {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Uncontrolled ascites",
                "criterions": [
                    {
                        "exact_snippets": "Uncontrolled ascites",
                        "criterion": "ascites",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Uncontrolled ascites",
                        "criterion": "ascites",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Use of any other chemotherapy, radiotherapy or experimental drug within 4 weeks prior to first study treatment date",
                "criterions": [
                    {
                        "exact_snippets": "Use of any other chemotherapy ... within 4 weeks prior to first study treatment date",
                        "criterion": "other chemotherapy use",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first study treatment date"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Use of any other ... radiotherapy ... within 4 weeks prior to first study treatment date",
                        "criterion": "other radiotherapy use",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first study treatment date"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Use of any other ... experimental drug within 4 weeks prior to first study treatment date",
                        "criterion": "other experimental drug use",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first study treatment date"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Use of any other chemotherapy ... within 4 weeks prior to first study treatment date",
                        "criterion": "other chemotherapy use",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first study treatment date"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Use of any other ... radiotherapy ... within 4 weeks prior to first study treatment date",
                        "criterion": "other radiotherapy use",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first study treatment date"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Use of any other ... experimental drug within 4 weeks prior to first study treatment date",
                        "criterion": "other experimental drug use",
                        "requirement": {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks prior to first study treatment date"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Pregnant or breastfeeding women.",
                "criterions": [
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding women",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "Pregnant",
                        "criterion": "pregnancy status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "breastfeeding women",
                        "criterion": "breastfeeding status",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* History of or suspected hypersensitivity to radiation or to galunisertib",
                "criterions": [
                    {
                        "exact_snippets": "History of or suspected hypersensitivity to radiation",
                        "criterion": "hypersensitivity to radiation",
                        "requirement": {
                            "requirement_type": "history or suspicion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of or suspected hypersensitivity ... to galunisertib",
                        "criterion": "hypersensitivity to galunisertib",
                        "requirement": {
                            "requirement_type": "history or suspicion",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "exact_snippets": "History of or suspected hypersensitivity to radiation",
                        "criterion": "hypersensitivity to radiation",
                        "requirement": {
                            "requirement_type": "history or suspicion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "History of or suspected hypersensitivity ... to galunisertib",
                        "criterion": "hypersensitivity to galunisertib",
                        "requirement": {
                            "requirement_type": "history or suspicion",
                            "expected_value": true
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any history of a serious medical or psychiatric condition that would prevent the patient from signing the informed consent form",
                "criterions": [
                    {
                        "exact_snippets": "Any history of a serious medical or psychiatric condition",
                        "criterion": "serious medical or psychiatric condition",
                        "requirement": {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any history of a serious medical or psychiatric condition",
                                "criterion": "serious medical or psychiatric condition",
                                "requirement": {
                                    "requirement_type": "history",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Any concurrent condition requiring the continued or anticipated use of systemic steroids beyond physiologic replacement dosing (excluding non-systemic inhaled, topical skin and/or eye drop-containing corticosteroids) or immunosuppressive therapy (excludes low-dose methotrexate). All other systemic corticosteroids above physiologic replacement dosing must be discontinued at least 4 weeks prior to first study treatment",
                "criterions": [
                    {
                        "exact_snippets": "Any concurrent condition requiring the continued or anticipated use of systemic steroids beyond physiologic replacement dosing",
                        "criterion": "systemic steroid use",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any concurrent condition requiring the continued or anticipated use of systemic steroids beyond physiologic replacement dosing",
                        "criterion": "systemic steroid use",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "physiologic replacement dosing"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Any concurrent condition requiring the continued or anticipated use of ... immunosuppressive therapy (excludes low-dose methotrexate)",
                        "criterion": "immunosuppressive therapy use",
                        "requirement": {
                            "requirement_type": "use",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "Any concurrent condition requiring the continued or anticipated use of ... immunosuppressive therapy (excludes low-dose methotrexate)",
                        "criterion": "immunosuppressive therapy use",
                        "requirement": {
                            "requirement_type": "exclusion",
                            "expected_value": "low-dose methotrexate"
                        }
                    },
                    {
                        "exact_snippets": "All other systemic corticosteroids above physiologic replacement dosing must be discontinued at least 4 weeks prior to first study treatment",
                        "criterion": "systemic corticosteroid discontinuation",
                        "requirement": {
                            "requirement_type": "discontinuation_time_before_treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    },
                    {
                        "exact_snippets": "All other systemic corticosteroids above physiologic replacement dosing must be discontinued at least 4 weeks prior to first study treatment",
                        "criterion": "systemic corticosteroid discontinuation",
                        "requirement": {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "physiologic replacement dosing"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "Any concurrent condition requiring the continued or anticipated use of systemic steroids beyond physiologic replacement dosing",
                                        "criterion": "systemic steroid use",
                                        "requirement": {
                                            "requirement_type": "use",
                                            "expected_value": true
                                        }
                                    },
                                    {
                                        "exact_snippets": "Any concurrent condition requiring the continued or anticipated use of systemic steroids beyond physiologic replacement dosing",
                                        "criterion": "systemic steroid use",
                                        "requirement": {
                                            "requirement_type": "dose",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 1,
                                                "unit": "physiologic replacement dosing"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Any concurrent condition requiring the continued or anticipated use of ... immunosuppressive therapy (excludes low-dose methotrexate)",
                                "criterion": "immunosuppressive therapy use",
                                "requirement": {
                                    "requirement_type": "use",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "Any concurrent condition requiring the continued or anticipated use of ... immunosuppressive therapy (excludes low-dose methotrexate)",
                                "criterion": "immunosuppressive therapy use",
                                "requirement": {
                                    "requirement_type": "exclusion",
                                    "expected_value": "low-dose methotrexate"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "and_criteria": [
                                    {
                                        "exact_snippets": "All other systemic corticosteroids above physiologic replacement dosing must be discontinued at least 4 weeks prior to first study treatment",
                                        "criterion": "systemic corticosteroid discontinuation",
                                        "requirement": {
                                            "requirement_type": "discontinuation_time_before_treatment",
                                            "expected_value": {
                                                "operator": ">=",
                                                "value": 4,
                                                "unit": "weeks"
                                            }
                                        }
                                    },
                                    {
                                        "exact_snippets": "All other systemic corticosteroids above physiologic replacement dosing must be discontinued at least 4 weeks prior to first study treatment",
                                        "criterion": "systemic corticosteroid discontinuation",
                                        "requirement": {
                                            "requirement_type": "dose",
                                            "expected_value": {
                                                "operator": ">",
                                                "value": 1,
                                                "unit": "physiologic replacement dosing"
                                            }
                                        }
                                    }
                                ]
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects with major abnormalities documented by ECHO with Doppler (for example, moderate or severe heart valve function defect) that is not stable for at least 6 months.. Note: Left ventricular [LV] ejection fraction <50% is allowed only if clinically stable for at least 6 months (evaluation based on the institutional lower limit of normal).",
                "criterions": [
                    {
                        "exact_snippets": "major abnormalities documented by ECHO with Doppler (for example, moderate or severe heart valve function defect) that is not stable for at least 6 months",
                        "criterion": "major cardiac abnormalities (by ECHO with Doppler)",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "major abnormalities documented by ECHO with Doppler (for example, moderate or severe heart valve function defect) that is not stable for at least 6 months",
                        "criterion": "major cardiac abnormalities (by ECHO with Doppler)",
                        "requirement": {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Left ventricular [LV] ejection fraction <50% is allowed only if clinically stable for at least 6 months (evaluation based on the institutional lower limit of normal)",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 50,
                                "unit": "%"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Left ventricular [LV] ejection fraction <50% is allowed only if clinically stable for at least 6 months (evaluation based on the institutional lower limit of normal)",
                        "criterion": "left ventricular ejection fraction",
                        "requirement": {
                            "requirement_type": "stability_duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "major abnormalities documented by ECHO with Doppler (for example, moderate or severe heart valve function defect) that is not stable for at least 6 months",
                                "criterion": "major cardiac abnormalities (by ECHO with Doppler)",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "major abnormalities documented by ECHO with Doppler (for example, moderate or severe heart valve function defect) that is not stable for at least 6 months",
                                "criterion": "major cardiac abnormalities (by ECHO with Doppler)",
                                "requirement": {
                                    "requirement_type": "stability_duration",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Left ventricular [LV] ejection fraction <50% is allowed only if clinically stable for at least 6 months (evaluation based on the institutional lower limit of normal)",
                                "criterion": "left ventricular ejection fraction",
                                "requirement": {
                                    "requirement_type": "quantity",
                                    "expected_value": {
                                        "operator": "<",
                                        "value": 50,
                                        "unit": "%"
                                    }
                                }
                            },
                            {
                                "not_criteria": {
                                    "exact_snippets": "Left ventricular [LV] ejection fraction <50% is allowed only if clinically stable for at least 6 months (evaluation based on the institutional lower limit of normal)",
                                    "criterion": "left ventricular ejection fraction",
                                    "requirement": {
                                        "requirement_type": "stability_duration",
                                        "expected_value": {
                                            "operator": ">=",
                                            "value": 6,
                                            "unit": "months"
                                        }
                                    }
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* A second primary malignancy that, in the judgment of the investigator, may affect the interpretation of results",
                "criterions": [
                    {
                        "exact_snippets": "A second primary malignancy",
                        "criterion": "second primary malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in the judgment of the investigator, may affect the interpretation of results",
                        "criterion": "potential to affect interpretation of results (as judged by investigator)",
                        "requirement": {
                            "requirement_type": "impact on interpretation of results",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "in the judgment of the investigator, may affect the interpretation of results",
                        "criterion": "potential to affect interpretation of results (as judged by investigator)",
                        "requirement": {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "A second primary malignancy",
                        "criterion": "second primary malignancy",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "in the judgment of the investigator, may affect the interpretation of results",
                                "criterion": "potential to affect interpretation of results (as judged by investigator)",
                                "requirement": {
                                    "requirement_type": "impact on interpretation of results",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "in the judgment of the investigator, may affect the interpretation of results",
                                "criterion": "potential to affect interpretation of results (as judged by investigator)",
                                "requirement": {
                                    "requirement_type": "investigator judgment",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Active drug or alcohol use or dependence as documented in the chart that, in the opinion of the investigator, would interfere with adherence to study requirements",
                "criterions": [
                    {
                        "exact_snippets": "Active drug or alcohol use or dependence as documented in the chart",
                        "criterion": "drug or alcohol use or dependence",
                        "requirement": {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    },
                    {
                        "exact_snippets": "Active drug or alcohol use or dependence as documented in the chart",
                        "criterion": "drug or alcohol use or dependence",
                        "requirement": {
                            "requirement_type": "documentation_status",
                            "expected_value": "documented in the chart"
                        }
                    },
                    {
                        "exact_snippets": "that, in the opinion of the investigator, would interfere with adherence to study requirements",
                        "criterion": "potential interference with adherence to study requirements",
                        "requirement": {
                            "requirement_type": "investigator_opinion",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "that, in the opinion of the investigator, would interfere with adherence to study requirements",
                        "criterion": "potential interference with adherence to study requirements",
                        "requirement": {
                            "requirement_type": "interference_with_adherence",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "Active drug or alcohol use or dependence as documented in the chart",
                                "criterion": "drug or alcohol use or dependence",
                                "requirement": {
                                    "requirement_type": "activity_status",
                                    "expected_value": "active"
                                }
                            },
                            {
                                "exact_snippets": "Active drug or alcohol use or dependence as documented in the chart",
                                "criterion": "drug or alcohol use or dependence",
                                "requirement": {
                                    "requirement_type": "documentation_status",
                                    "expected_value": "documented in the chart"
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "that, in the opinion of the investigator, would interfere with adherence to study requirements",
                                "criterion": "potential interference with adherence to study requirements",
                                "requirement": {
                                    "requirement_type": "investigator_opinion",
                                    "expected_value": true
                                }
                            },
                            {
                                "exact_snippets": "that, in the opinion of the investigator, would interfere with adherence to study requirements",
                                "criterion": "potential interference with adherence to study requirements",
                                "requirement": {
                                    "requirement_type": "interference_with_adherence",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "identified_line": {
                "line": "Laboratory Test Required Value Absolute neutrophil count ≥1.5 x 10^9/L Platelet count ≥100 x 10^9/L Hemoglobin ≥9.0 x 10^9/L Alanine transaminase ≤2.5 x ULN Aspartate aminotransferase ≤2.5 x ULN Serum creatinine or CrCl ≤2.0 x ULN Total Bilirubin ≤1.5 x ULN",
                "criterions": [
                    {
                        "exact_snippets": "Absolute neutrophil count ≥1.5 x 10^9/L",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelet count ≥100 x 10^9/L",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hemoglobin ≥9.0 x 10^9/L",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "x 10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Alanine transaminase ≤2.5 x ULN",
                        "criterion": "alanine transaminase",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Aspartate aminotransferase ≤2.5 x ULN",
                        "criterion": "aspartate aminotransferase",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Serum creatinine or CrCl ≤2.0 x ULN",
                        "criterion": "serum creatinine or creatinine clearance (CrCl)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total Bilirubin ≤1.5 x ULN",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Absolute neutrophil count \u00181.5 x 10^9/L",
                        "criterion": "absolute neutrophil count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1.5,
                                "unit": "x 10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Platelet count \u0018100 x 10^9/L",
                        "criterion": "platelet count",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "x 10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Hemoglobin \u00189.0 x 10^9/L",
                        "criterion": "hemoglobin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9.0,
                                "unit": "x 10^9/L"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Alanine transaminase \u00182.5 x ULN",
                        "criterion": "alanine transaminase",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Aspartate aminotransferase \u00182.5 x ULN",
                        "criterion": "aspartate aminotransferase",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Serum creatinine or CrCl \u00182.0 x ULN",
                        "criterion": "serum creatinine or creatinine clearance (CrCl)",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.0,
                                "unit": "x ULN"
                            }
                        }
                    },
                    {
                        "exact_snippets": "Total Bilirubin \u00181.5 x ULN",
                        "criterion": "total bilirubin",
                        "requirement": {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Local or loco-regional therapy (ie surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) must have been completed ≥4 weeks prior to enrollment",
                "criterions": [
                    {
                        "exact_snippets": "Local or loco-regional therapy (ie surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) must have been completed ≥4 weeks prior to enrollment",
                        "criterion": "local or loco-regional therapy",
                        "requirement": {
                            "requirement_type": "completion_time_before_enrollment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "exact_snippets": "Local or loco-regional therapy (ie surgery, radiation therapy, hepatic arterial embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol injection or cryoablation) must have been completed \u00194 weeks prior to enrollment",
                        "criterion": "local or loco-regional therapy",
                        "requirement": {
                            "requirement_type": "completion_time_before_enrollment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* No history of non-malignancy AIDS defining conditions other than low CD4+ count.",
                "criterions": [
                    {
                        "exact_snippets": "No history of non-malignancy AIDS defining conditions other than low CD4+ count",
                        "criterion": "history of non-malignancy AIDS defining conditions",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    },
                    {
                        "exact_snippets": "No history of non-malignancy AIDS defining conditions other than low CD4+ count",
                        "criterion": "history of non-malignancy AIDS defining conditions",
                        "requirement": {
                            "requirement_type": "exception",
                            "expected_value": "low CD4+ count"
                        }
                    }
                ]
            },
            "logical_structure": {
                "and_criteria": [
                    {
                        "not_criteria": {
                            "not_criteria": {
                                "exact_snippets": "No history of non-malignancy AIDS defining conditions other than low CD4+ count",
                                "criterion": "history of non-malignancy AIDS defining conditions",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        }
                    },
                    {
                        "or_criteria": [
                            {
                                "not_criteria": {
                                    "not_criteria": {
                                        "exact_snippets": "No history of non-malignancy AIDS defining conditions other than low CD4+ count",
                                        "criterion": "history of non-malignancy AIDS defining conditions",
                                        "requirement": {
                                            "requirement_type": "presence",
                                            "expected_value": true
                                        }
                                    }
                                }
                            },
                            {
                                "exact_snippets": "No history of non-malignancy AIDS defining conditions other than low CD4+ count",
                                "criterion": "history of non-malignancy AIDS defining conditions",
                                "requirement": {
                                    "requirement_type": "exception",
                                    "expected_value": "low CD4+ count"
                                }
                            }
                        ]
                    }
                ]
            }
        }
    ],
    "failed_exclusion": [
        {
            "identified_line": {
                "line": "* Prior malignancies. Patients with carcinoma in-situ of any origin and patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma) as judged by the Lilly clinical research physician (CRP), are eligible.",
                "criterions": [
                    {
                        "exact_snippets": "Prior malignancies. Patients with carcinoma in-situ of any origin ... are eligible.",
                        "criterion": "carcinoma in-situ of any origin",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma) as judged by the Lilly clinical research physician (CRP), are eligible.",
                        "criterion": "prior malignancies",
                        "requirement": {
                            "requirement_type": "remission_status",
                            "expected_value": "in remission"
                        }
                    },
                    {
                        "exact_snippets": "patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma) as judged by the Lilly clinical research physician (CRP), are eligible.",
                        "criterion": "prior malignancies",
                        "requirement": {
                            "requirement_type": "likelihood of recurrence",
                            "expected_value": "very low"
                        }
                    },
                    {
                        "exact_snippets": "patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma) as judged by the Lilly clinical research physician (CRP), are eligible.",
                        "criterion": "prior malignancies",
                        "requirement": {
                            "requirement_type": "clinical research physician judgment",
                            "expected_value": true
                        }
                    }
                ]
            },
            "logical_structure": {
                "or_criteria": [
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "prior malignancies. Patients with carcinoma in-situ of any origin ... are eligible.",
                                "criterion": "carcinoma in-situ of any origin",
                                "requirement": {
                                    "requirement_type": "presence",
                                    "expected_value": true
                                }
                            }
                        ]
                    },
                    {
                        "and_criteria": [
                            {
                                "exact_snippets": "patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma) as judged by the Lilly clinical research physician (CRP), are eligible.",
                                "criterion": "prior malignancies",
                                "requirement": {
                                    "requirement_type": "remission_status",
                                    "expected_value": "in remission"
                                }
                            },
                            {
                                "exact_snippets": "patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma) as judged by the Lilly clinical research physician (CRP), are eligible.",
                                "criterion": "prior malignancies",
                                "requirement": {
                                    "requirement_type": "likelihood of recurrence",
                                    "expected_value": "very low"
                                }
                            },
                            {
                                "exact_snippets": "patients with prior malignancies who are in remission and whose likelihood of recurrence is very low (such as basal cell carcinoma) as judged by the Lilly clinical research physician (CRP), are eligible.",
                                "criterion": "prior malignancies",
                                "requirement": {
                                    "requirement_type": "clinical research physician judgment",
                                    "expected_value": true
                                }
                            }
                        ]
                    }
                ]
            }
        },
        {
            "identified_line": {
                "line": "* Subjects with a history of or evidence of cardiac disease during screening, defined as any one of the following: myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, uncontrolled hypertension.",
                "criterions": [
                    {
                        "exact_snippets": "myocardial infarction within 6 months prior to study entry",
                        "criterion": "myocardial infarction",
                        "requirement": {
                            "requirement_type": "history within timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to study entry"
                            }
                        }
                    },
                    {
                        "exact_snippets": "unstable angina pectoris",
                        "criterion": "unstable angina pectoris",
                        "requirement": {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    },
                    {
                        "exact_snippets": "New York Heart Association Class III/IV congestive heart failure",
                        "criterion": "congestive heart failure",
                        "requirement": {
                            "requirement_type": "NYHA class",
                            "expected_value": [
                                "III",
                                "IV"
                            ]
                        }
                    },
                    {
                        "exact_snippets": "uncontrolled hypertension",
                        "criterion": "hypertension",
                        "requirement": {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    }
                ]
            },
            "logical_structure": {
                "exact_snippets": "failed",
                "criterion": "failed",
                "requirement": {
                    "requirement_type": "failed",
                    "expected_value": "failed"
                }
            }
        }
    ],
    "failed_miscellaneous": []
}